China: Cross-asset inflows and policy shifts – BNY
BNY’s Bob Savage highlights China as the only emerging market currently seeing net buying across equities, bonds and currency, even as domestic data remain mixed. He notes that fixed income inflows are supported by lower policy rates, while authorities tighten outbound investment rules and retain scope to allow the renminbi to appreciate in a controlled, export-sensitive manner.
Cross-asset inflows and tighter controls
"Meanwhile, there is one emerging market where all assets are now being net-bought: China."
"Given input price risks and a large legacy surplus, there is capacity and a solid policy rationale to let the renminbi appreciate despite domestic pressures."
"However, the pace will be controlled and subject to export/economic performance, and the cautious inflows also seem to reflect such a policy stance."
"China has announced new outbound investment regulations effective July 1 that significantly strengthen government oversight of overseas transactions involving Chinese investors, technology, data and national security."
"The regulations form part of a wider effort to strengthen export controls, protect strategic technologies, reinforce supply chain security and increase China’s ability to respond to Western sanctions and investment restrictions."
(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash

25 Days, Four Launches in Sight! Rocket Lab (RKLB.US) Accelerates Rocket Launches to Advance Its Ambitious "Space AI Infrastructure" Goals
After another successful mission, Rocket Lab's 97th Electron rocket is now positioned at the launch pad. This flight will be Rocket Lab's fourth launch in 25 days and its 18th launch in 2026.
